Is the expression of matrix metalloproteinases (MMP-2, -9) and tissue inhibitors of metalloproteinases (TIMP-1, -2, and -3) associated with angiogenesis and clinicopathological features for breast cancer?

Authors

  • Suada Kuskunović-Vlahovljak Department of Pathology, School of Medicine, University of Sarajevo
  • Nina Čamdžić Department of Pathology, School of Medicine, University of Sarajevo
  • Svjetlana Radović Department of Pathology, School of Medicine, University of Sarajevo
  • Mirsad Dorić Department of Pathology, School of Medicine, University of Sarajevo
  • Mirsad Babić Department of Pathology, School of Medicine, University of Sarajevo
  • Edina Lazović Salčin Department of Pathology, School of Medicine, University of Sarajevo
  • Lejla Džananović Department of Epidemiology and Biostatistics, School of Medicine, University of Sarajevo

DOI:

https://doi.org/10.17532/jhsci.2017.460

Keywords:

Breast cancer, matrix metalloproteinases, tissue inhibitors of metalloproteinases, angiogenesis, endoglin, immunohistochemistry

Abstract

Introduction: Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are involved in the progression of several tumors, including breast cancer. Our aim was to investigate the association of immunohistochemical expression of protein MMP-2, and -9 and tissue inhibitors TIMP-1,-2,-3 by tumoral cells in the process of angiogenesis and to define their relation with clinicopathological features for breast cancer.

Methods: Immunohistochemical analysis of MMP-2,-9, TIMP-1,-2,-3, endoglin/CD105, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status was performed on 79 tissue samples of breast cancer with axillary lymph node dissection.

Results: Statistically significant difference was found between mean age of patients and tissue inhibitors of metalloproteinase (TIMP-1) expression status (p=0.008), i.e., women with TIMP-1 negative tumors were on average younger (mean age 46.5) compared to women with TIMP-1 positive tumors (mean age 58.1); TIMP-2 expression status showed association with ER status (p=0.017), while TIMP-3 negative tumors were on average more frequently ER and PR negative (p=0.016; p=0.027). Status of protein expression of MMP-9 was associated with TIMP-1 protein expression status (p=0.033), i.e., breast cancers with overexpression of protein MMP-9 were more frequently TIMP-1 protein positive.

Conclusion: Only TIMPs were associated with clinicopathological features for breast cancer. TIMP-2 expression was associated with worse (TIMP-2 positive tumors were frequently ER-negative), while TIMP-3 expression in tumoral cells was associated with better clinicopathological features for breast cancer (TIMP-3 positive tumors were frequently ER and PR positive).

Downloads

Download data is not yet available.

Published

2017-12-20

How to Cite

Kuskunović-Vlahovljak, S., Čamdžić, N., Radović, S., Dorić, M., Babić, M., Lazović Salčin, E., & Džananović, L. (2017). Is the expression of matrix metalloproteinases (MMP-2, -9) and tissue inhibitors of metalloproteinases (TIMP-1, -2, and -3) associated with angiogenesis and clinicopathological features for breast cancer?. Journal of Health Sciences, 7(3), 158-168. https://doi.org/10.17532/jhsci.2017.460

Issue

Section

Research articles